Prediction of Treatment Response at 6 Months by Combinatorial Analysis of Serum Biomarkers in Biotherapy Naive SpA

NCT03561649 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Spondylitis, Ankylosing

Interventions

DRUG: Adalimumab

Sponsor

University Hospital, Grenoble

Collaborators

[object Object]